Diabetes & Metabolic Syndrome: Clinical Research & Reviews
ReviewDiabetes and Anemia: International Diabetes Federation (IDF) – Southeast Asian Region (SEAR) position statement
Introduction
The co-existence of anemia and diabetes is being increasingly explored as it has a major impact on the overall health status of the patients [1], [2], [3]. The prevalence of concurrent anemia and diabetes mellitus (both type 1 and type 2) ranges from 14% to 45% in different ethnic populations worldwide [4], [5], [6], [7]. Although anemia and diabetes mellitus are increasingly recognized as a major health conditions [8], [9], [10], little is known about the co-existence of these conditions in south-east Asian countries like India, Sri Lanka, Bangladesh, Nepal, Mauritius and Maldives. In India, the prevalence of anemia in patients with diabetes was estimated to be approximately 18% [11], [12].
The risk of anemia in patients with diabetes is estimated to be two- to three-times higher than that of patients without diabetes [5], [13]. Early evidences indicate that the incidence of anemia in patients with diabetes mellitus is typically associated with presence of kidney disease [13], [14]. The risk of developing anemia in patients with diabetes mellitus associated with kidney disease is greater than in those patients having kidney disease of other causes [14]. Nonetheless, the early occurrence of anemia in patients without kidney disease suggests existence of some other causes of anemia in these patients [5]. Patients with poor glycemic control are at a higher risk of developing anemia than patients having good glycemic control; and the risk further increases with onset of kidney disease [15].
Chronic anemia in diabetes mellitus predicts the progression of macrovascular complications such as cardiovascular disease and stroke as well as microvascular complications such as nephropathy and retinopathy [16]. Indeed, the constellation of these modifiable risk factors is often overlooked and if untreated, it is associated with poor outcomes, including impaired quality of life, increased hospitalization and all-cause mortality [3], [17]. Therefore, appropriate screening, prompt detection and correction of anemia are crucial to improve the clinical outcomes in patients with diabetes mellitus. The purpose of this International Diabetes Federation (IDF) – Southeast Asian Region (SEAR) position statement is to provide a comprehensive overview and evidence-based recommendations for the management of anemia in patients with diabetes mellitus.
Section snippets
Pathophysiology of anemia in diabetes: multifactorial mechanism
The etiology and pathophysiology of anemia in both type 1 and type 2 diabetes mellitus is considered to be multifactorial.
Medications
Patients with diabetes mellitus are treated with antihyperglycemic agents (AHAs) along with multiple medications for accompanying comorbid conditions. Metformin, often used as a first line treatment for diabetes mellitus, has been potentially associated with vitamin B12 deficiency due to malabsorption of vitamin B12, contributing to megaloblastic anemia [27]. Reduction in absorption of vitamin B12 may typically begin as early as four months after initiation of the drug; however the clinical
Iron overload and risk of diabetes mellitus
Iron overload status or hemochromatosis can be distinguished as primary or secondary. The primary form of hemochromatosis (also known as hereditary hemochromatosis) is a genetic condition characterized by iron deposition in the parenchymal cells. It usually results from mutations in the genes encoding proteins that are involved in iron homeostasis. Secondary hemochromatosis occurs in conditions where excess iron is secondary to other disease states (e.g. multiple transfusions in β thalassemia
Diabetic kidney disease
Diabetic nephropathy is a common consequence of type 2 diabetes mellitus and it is observed in almost 5% of newly diagnosed diabetes patients [79]. Further, within 10 years of diagnosis, nearly 30–40% of patients may progress to diabetic nephropathy [79]. In these patients, anemia is a common manifestation and can be observed even before any demonstrable changes in renal function [80], [81]. The risk of anemia in patients with diabetes having kidney disease is 2–10-fold greater than in patients
Screening of anemia
According to the World Health Organization (WHO), anemia is defined as level of hemoglobin <13 g/dL in men, <12 g/dL in normal women and <11 g/dL in pregnant women [108]. Evaluation of mean corpuscular hemoglobin (MCH) or mean corpuscular volume (MCV) can distinguish macrocytic anemia (vitamin B12 or folate deficiency) from microcytic or normocytic [109]. Vitamin B12 or folate deficiency can be further confirmed based on the serum levels [110]. Iron status can be clinically assessed by measuring
Management of anemia
A prompt correction of anemia in patients with diabetes (with or without kidney disease) has shown to improve the overall clinical outcome and quality of life and reduce the risk of complications and mortality [114], [115]. The treatment strategy must be made based on the severity of anemia, underlying causes and comorbid conditions. Although the target for maintaining optimal hemoglobin is still undefined, it should be individualized based on the age, clinical status and treatment response. In
Conclusions
In patients with diabetes mellitus (with or without CKD), prompt detection and correction of anemia is important to reduce the risk of adverse outcomes. Treatment with oral or intravenous iron preparations and ESA needs to be individualized based on the patients’ clinical status and comorbid conditions. Overcorrection of anemia with hemoglobin level exceeding 13 g/dL, especially when treating with ESA, can be detrimental. Patients receiving treatment for anemia should be routinely monitored
References (119)
- et al.
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study
Kidney Int
(2003) - et al.
The epidemiology of hemoglobin levels in patients with type 2 diabetes
Am J Kidney Dis
(2006) - et al.
IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030
Diabetes Res Clin Pract
(2011) - et al.
Implications of DPP4 modification of proteins that regulate stem/progenitor and more mature cell types
Blood
(2013) - et al.
Iron management in chronic kidney disease: conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference
Kidney Int
(2016) - et al.
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus
Clin Ther
(2001) - et al.
Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction
J Am Coll Cardiol
(2005) - et al.
The role of the renin-angiotensin system in the regulation of erythropoiesis
Am J Kidney Dis
(2010) - et al.
Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: a randomized open-label prospective trial
Diabetes Res Clin Pract
(2016) - et al.
Iron and diabetes risk
Cell Metab
(2013)
HFE-associated hereditary hemochromatosis
Genet Med
Effects of iron overload on chronic metabolic diseases
Lancet Diabetes Endocrinol
Hemochromatosis mutations in the general population: iron overload progression rate
Blood
Haemochromatosis
Lancet (London, England)
Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis
Clin Chim Acta Int J Clin Chem
Pathways underlying iron accumulation in human nonalcoholic fatty liver disease
Am J Clin Nutr
Hepcidin and iron-related gene expression in subjects with Dysmetabolic Hepatic Iron Overload
J Hepatol
Iron status in women with and without gestational diabetes mellitus
J Diabetes Complications
Is oxidative stress induced by iron status associated with gestational diabetes mellitus?
J Trace Elem Med Biol
Targets to retard the progression of diabetic nephropathy
Kidney Int
Outcome studies in diabetic nephropathy
Semin Nephrol
TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4
Nephrol Ther
The relationship between hemoglobin levels and diabetic retinopathy
J Clin Epidemiol
Anemia as a risk factor for cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study
J Am Coll Cardiol
Chronic kidney disease and cardiovascular disease in the Medicare population
Kidney Int Suppl
The anaemia of silent diabetic nephropathy-prevalence, physiopathology, and management
Acta Clin Belg
Anaemia in diabetes: is there a rationale to TREAT?
Diabetologia
Anaemia and kidney dysfunction in Caribbean type 2 diabetic patients
Cardiovasc Diabetol
Unrecognized anemia in patients with diabetes: a cross-sectional survey
Diabetes Care
Prevalence of anaemia in patients with diabetes mellitus
Irish J Med Sci
The global prevalence of anaemia in 2011
IDF diabetes atlas
Study of prevalence of anaemia in patients with type 2 diabetes mellitus
Scholars J Appl Med Sci
Prevalence of anemiain patients with type 2 diabetes mellitus at Gandhinagar, Gujarat, India
Int Arch Integr Med
Diabetes mellitus increases the prevalence of anemia in patients with chronic kidney disease: a nested case-control study
World J Nephrol
Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994)
Arch Intern Med
The incidence of anemia and the impact of poor glycemic control in type-2 diabetic patients with renal insufficiency
J Biol Agric Healthc
Screening for chronic kidney disease in patients with diabetes: are we missing the point? Nature clinical practice
Nephrology
Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease
J Am Soc Nephrol JASN
Autoimmune gastritis in type 1 diabetes: a clinically oriented review
J Clin Endocrinol Metab
Anemia with erythropoietin deficiency occurs early in diabetic nephropathy
Diabetes Care
Erythropoietic stress and anemia in diabetes mellitus
Nat Rev Endocrinol
Erythropoietin depletion and anaemia in diabetes mellitus
Diabet Med
Anemia and diabetes in the absence of nephropathy
Diabetes Care
Functional erythropoietin deficiency in patients with Type 2 diabetes and anaemia
Diabet Med
Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis
Nat Med
Risk factors of vitamin B(12) deficiency in patients receiving metformin
Arch Intern Med
Metformin-associated vitamin B12 deficiency
Arch Intern Med
Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial
J Intern Med
Evaluation of vitamin B12 monitoring in a veteran population on long-term, high-dose metformin therapy
Ann Pharmacother
Cited by (55)
HbA1c without Complete Blood Count: What are we missing? — A viewpoint from South-East Asia
2023, Archives of Medical ResearchFrequency of iron deficiency anemia in type 2 diabetes - Insights from tertiary diabetes care centres across India
2022, Diabetes and Metabolic Syndrome: Clinical Research and ReviewsCitation Excerpt :Numerous factors have been proposed to explain the anemia noted in people with T2DM. Anemia can be caused by iron and erythropoietin deficiency, as well as hypo responsiveness to erythropoietin in individuals with diabetes with renal disease or even with relatively normal glomerular filtration rates [23]. Often, anemia work-up is missed and link between anemia and kidney disease is overlooked [24].